Cargando…

Impaired subendocardial perfusion in patients with metabolic syndrome

BACKGROUND: Metabolic Syndrome (MS) is associated to vascular damage, increased arterial stiffness, and impaired myocardial perfusion. Subendocardial viability ratio (SEVR) is a noninvasive estimation of myocardial workload, oxygen supply, and perfusion. The aim of the study was to describe the rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Fantin, Francesco, Giani, Anna, Gasparini, Ludovico, Rossi, Andrea P, Zoico, Elena, Mazzali, Gloria, Zamboni, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591647/
https://www.ncbi.nlm.nih.gov/pubmed/34772282
http://dx.doi.org/10.1177/14791641211047135
_version_ 1784599295737987072
author Fantin, Francesco
Giani, Anna
Gasparini, Ludovico
Rossi, Andrea P
Zoico, Elena
Mazzali, Gloria
Zamboni, Mauro
author_facet Fantin, Francesco
Giani, Anna
Gasparini, Ludovico
Rossi, Andrea P
Zoico, Elena
Mazzali, Gloria
Zamboni, Mauro
author_sort Fantin, Francesco
collection PubMed
description BACKGROUND: Metabolic Syndrome (MS) is associated to vascular damage, increased arterial stiffness, and impaired myocardial perfusion. Subendocardial viability ratio (SEVR) is a noninvasive estimation of myocardial workload, oxygen supply, and perfusion. The aim of the study was to describe the relation between arterial stiffness, SEVR, and cardio-metabolic risk factors. METHODS: A cohort of 55 patients, aged 59.9 ± 10.8 years, was studied; 28 subjects (50.9%) had metabolic syndrome. All patients underwent a clinical evaluation and blood venous sampling, to assess glico-lipid profile. Applanation tonometry was performed, to obtain pulse wave analysis and SEVR values. RESULTS: In the overall study population, SEVR showed negative associations with mean (r = −0.301; p = 0.026) and systolic (borderline relation, r = −0.257; p = 0.058) arterial pressure. Metabolic syndrome patients presented lower level of SEVR (p = 0.012), even after adjusting for age, sex, and mean arterial pressure (p = 0.040). Subdividing the study population by the number of metabolic syndrome components, SEVR significantly decreased as the number of Metabolic Syndrome components increased (p for trend 0.005). In a logistic backward regression analysis, both metabolic syndrome and mean arterial pressure resulted significant predictors of SEVR, accounting for 18% of variance. CONCLUSION: The reduced SEVR in metabolic syndrome patients could be an important pathophysiological determinant of the increased cardiovascular risk.
format Online
Article
Text
id pubmed-8591647
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-85916472021-11-16 Impaired subendocardial perfusion in patients with metabolic syndrome Fantin, Francesco Giani, Anna Gasparini, Ludovico Rossi, Andrea P Zoico, Elena Mazzali, Gloria Zamboni, Mauro Diab Vasc Dis Res Original Article BACKGROUND: Metabolic Syndrome (MS) is associated to vascular damage, increased arterial stiffness, and impaired myocardial perfusion. Subendocardial viability ratio (SEVR) is a noninvasive estimation of myocardial workload, oxygen supply, and perfusion. The aim of the study was to describe the relation between arterial stiffness, SEVR, and cardio-metabolic risk factors. METHODS: A cohort of 55 patients, aged 59.9 ± 10.8 years, was studied; 28 subjects (50.9%) had metabolic syndrome. All patients underwent a clinical evaluation and blood venous sampling, to assess glico-lipid profile. Applanation tonometry was performed, to obtain pulse wave analysis and SEVR values. RESULTS: In the overall study population, SEVR showed negative associations with mean (r = −0.301; p = 0.026) and systolic (borderline relation, r = −0.257; p = 0.058) arterial pressure. Metabolic syndrome patients presented lower level of SEVR (p = 0.012), even after adjusting for age, sex, and mean arterial pressure (p = 0.040). Subdividing the study population by the number of metabolic syndrome components, SEVR significantly decreased as the number of Metabolic Syndrome components increased (p for trend 0.005). In a logistic backward regression analysis, both metabolic syndrome and mean arterial pressure resulted significant predictors of SEVR, accounting for 18% of variance. CONCLUSION: The reduced SEVR in metabolic syndrome patients could be an important pathophysiological determinant of the increased cardiovascular risk. SAGE Publications 2021-11-12 /pmc/articles/PMC8591647/ /pubmed/34772282 http://dx.doi.org/10.1177/14791641211047135 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Fantin, Francesco
Giani, Anna
Gasparini, Ludovico
Rossi, Andrea P
Zoico, Elena
Mazzali, Gloria
Zamboni, Mauro
Impaired subendocardial perfusion in patients with metabolic syndrome
title Impaired subendocardial perfusion in patients with metabolic syndrome
title_full Impaired subendocardial perfusion in patients with metabolic syndrome
title_fullStr Impaired subendocardial perfusion in patients with metabolic syndrome
title_full_unstemmed Impaired subendocardial perfusion in patients with metabolic syndrome
title_short Impaired subendocardial perfusion in patients with metabolic syndrome
title_sort impaired subendocardial perfusion in patients with metabolic syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591647/
https://www.ncbi.nlm.nih.gov/pubmed/34772282
http://dx.doi.org/10.1177/14791641211047135
work_keys_str_mv AT fantinfrancesco impairedsubendocardialperfusioninpatientswithmetabolicsyndrome
AT gianianna impairedsubendocardialperfusioninpatientswithmetabolicsyndrome
AT gaspariniludovico impairedsubendocardialperfusioninpatientswithmetabolicsyndrome
AT rossiandreap impairedsubendocardialperfusioninpatientswithmetabolicsyndrome
AT zoicoelena impairedsubendocardialperfusioninpatientswithmetabolicsyndrome
AT mazzaligloria impairedsubendocardialperfusioninpatientswithmetabolicsyndrome
AT zambonimauro impairedsubendocardialperfusioninpatientswithmetabolicsyndrome